HealthQuill AstraZeneca
British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.
Drugs Health Pharma

AstraZeneca acquires France’s Amolyt Pharma for $1.05 billion

British-Swedish AstraZeneca has acquired Amolyt Pharma for $1.05 billion to gain access to Lyon, France-based company’s rare disease, late-stage pipeline.

Read More
The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed an extended nine months of survival.
Drugs Health Pharma

AstraZeneca’s medicine for non-small lung cancer gets EU nod

HQ Team July 5, 2024: The Europen Union has approved AstraZeneca’s Tagrisso along with chemotherapy treatment for lung cancer patients after trials showed.

Read More
AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.
Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Read More
The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.
Drugs Health Pharma

FDA gives nod for AstraZeneca’s Imfinzi to treat endometrial cancer

The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.

Read More
AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company statement.
Drugs Health Pharma

AstraZeneca’s trial drug for mantle cell lymphoma raises survival rate

AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company.

Read More
AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according to a company statement.
Drugs Health Pharma

FDA approves AstraZeneca’s type-2 diabetes drug in US market

AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.

Read More
AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.
Drugs Health Pharma

AstraZeneca completes $2.4 billion acquisition of Fusion Pharma

AstraZeneca announced the completion of the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, for $2.4 billion.

Read More
AstraZeneca, Daiichi’s breast cancer drug trial results show improvement in progression-free survival
Drugs Health Pharma

AstraZeneca, Daiichi’s breast cancer drug trials show rise in survival

HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.

Read More
The US drug regulator has approved Amen’s biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug Administration.
Drugs Health Pharma

US drug regulator clears Amgen’s biosimilar to treat rare blood disorder

The US drug regulator has approved Amen’s biosimilar, Bkemv,  to treat rare blood disorders, according to a statement from the Food and Drug.

Read More
AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in a statement.
Drugs Health Pharma

AstraZeneca plans to build $1.5 billion drug making facility in Singapore 

HQ Team May 20, 2024: AstraZeneca plans to build a $1.5 billion facility to make antibody-drug conjugates in Singapore, the company announced in.

Read More